Comparison of clinical outcomes between sorafenib and hepatic artery infusion chemotherapy in advanced hepatocellular carcinoma: A STROBE-compliant article

Sorafenib is the most widely used multikinase inhibitor in patients with advanced hepatocellular carcinoma (HCC). Despite its efficacy, only a small proportion of patients experience tumor regression. Hepatic artery infusion chemotherapy (HAIC) can be used as an alternative treatment for HCC. A tota...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Min Kyu, Park, Jung Gil, Lee, Heon Ju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944539/
https://www.ncbi.nlm.nih.gov/pubmed/29703062
http://dx.doi.org/10.1097/MD.0000000000010611

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944539/
https://www.ncbi.nlm.nih.gov/pubmed/29703062
http://dx.doi.org/10.1097/MD.0000000000010611

Ejemplares similares